Ribonuclease L inhibitor as an indicator of chronic fatigue synd

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 792, 435372, 530350, G01N 3353

Patent

active

057668590

ABSTRACT:
Chronic fatigue syndrome in an individual is diagnosed by determining the level of RNase L inhibitor mRNA or protein in peripheral blood mononuclear cells. Significantly decreased levels of RLI mRNA or protein compared to healthy control individuals indicates the presence of chronic fatigue syndrome.

REFERENCES:
patent: 5258369 (1993-11-01), Carter
E. Barker, et al. (1994), Immunologic abnormalities associated with chronic fatigue syndrome. Clinical Infectious Diseases 18 (Suppl. 1):S136-41.
M. Becker-Andre, et al. (1989), Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Research, 17(22):9437-9446.
C. Bisbal, et al. (1995), Cloning and characterization of a RNase L inhibitor. The Journal of Biological Chemisry 270(22):13308-13317.
D. Ferbus, et al. (1981), The 2'2' oligoadenylate synthetase has a multifunctional 2'5' nucleotidyl-transferase activity. Biochemical and Biophysical Research Communications 100(2):847-856.
G. Floyd-Smith, et al. (1981), Interferon action: RNA cleavage pattern of a (2'-5') oligoadenylate-dependent endonuclease. Science 212:1030-1032.
K. Fukuda, et al. (1994), The chronic fatigue syndrome: a comprehensive approach to its definition and study. Annals of Internal Medicine 121(12):953-959.
G. Gilliland, et al. (1990), Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:2725-2729.
Immunsciences Lab., Inc. (approx. Jun. 1995), new product announcement.
N.G. Klimas, et al. (1990), Immunologic abnormalities in chronic fatigue syndrome. Journal of Clinical Microbiology 28(6):1403-1410.
P. Lengyel (1993), Tumor-suppressor genes: news about the interferon connection. Proc. Natl. Acad. Sci. USA90:5893-5895.
T. Lion (1994), Clinical implications of qualitative and qualitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplantation 14:505-509.
E. Mordechai, et al. (1995), Activation of the interferon-inducible enzymes, 2', 5'-oligoadenylate synthetase and PKR by human T-cell leukemia virus type I rex-response element. Virology 206:913-922.
L.J.A. Morrison, et al. (1991), Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin. exp. Immunol. 83:441-446.
S. Pestka, et al. (1987), Interferons and their actions. Ann. Rev. Biochem. 56:727-777.
T. Salehzada, et al. (1993), 2',5'-Oligoadenylate-dependent RNase L is a dimer of regulatory and catalytic subunits. The Journal of Biological Chemistry 268(11):7733-7740.
P.D. Siebert, et al. (1993), PCR Mimics: competitive DNA fragments for use as internal standards in quantitative PCR. BioTechniques 14(2):244-249.
R.H. Silverman, et al. (1982), Control of the ppp(A2'p).sub.n. A system in HeLa cells. Eur. J. Biochem. 124:131-138.
R.J. Suhadolnik, et al. (1994), Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clinical Infectious Diseases 18(Suppl. 1):S96-104.
D.H. Wreschner, et al. (1981), Interferon action-sequence specificity of the ppp(A2'p).sub.n A-dependent ribonuclease. Nature 289:414-417.
A. Zhou, et al. (1993), Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72:753-765.
Bleijenberg et al., Enteroviruses and the chronic fatigue syndrome, Clinical Infect. Dis., 19:860-864, Nov. 1994.
Honda et al., Japanese patients with chronic fatigue syndrome are negative for known retroviruses, Microbiol. Immunol., 37(10):779-784, Dec. 1993.
Suhadolnik et al., Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(l)-Poly(C12U) in chronic fatigue syndrome, In Vivo, 8:599-604, Nov. 1994.
Merck Manual, 14th Ed., Merck Sharp & Dohme Research Laboratories: Rahway, NJ, p.2177, 1982.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Ribonuclease L inhibitor as an indicator of chronic fatigue synd does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribonuclease L inhibitor as an indicator of chronic fatigue synd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribonuclease L inhibitor as an indicator of chronic fatigue synd will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1724043

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.